Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis

哈姆德 医学 不利影响 内科学 萧条(经济学) 荟萃分析 产后抑郁症 抗抑郁药 胃肠病学 显著性差异 怀孕 生物 遗传学 宏观经济学 经济 海马体
作者
Lingning Wang,Yan Fan,Jiangmen He,Heng Liu,Feng Chen,Hongying Dan,Juan Zhao,Jiao Zhang,Tao Wang,Xinru Liu
出处
期刊:Evidence-based Complementary and Alternative Medicine [Hindawi Publishing Corporation]
卷期号:2022: 1-16 被引量:1
标识
DOI:10.1155/2022/5260235
摘要

To evaluate the efficacy and safety of Shuganjieyu capsule alone or in combination with other antidepressants in the treatment of postpartum depression.Related control and randomized studies till August 1, 2021, were retrieved from the following databases: PubMed, Cochrane, CNKI, CMB, Wan-Fang, and VIP. Outcomes included HAMD reduction from baseline, response rate, and adverse events rate. Review Manager 5.3 was used in the present meta-analysis.16 studies including 1409 participants were included in the present study. In comparison of single Shuganjieyu capsule versus regular antidepressant, 8, 6, and 4-week HAMD reduction of the Shuganjieyu group were significantly higher (8-week MD: 3.1 (1.54, 4.66), p < 0.0001; 6-week MD: 0.71 (0.10, 1.31), p=0.02; and 4-week MD: 0.82 (0.34, 1.30), p=0.0008), response rates were comparable for the two groups (OR: 1.51 (0.87, 2.63), p=0.014), and the adverse event rate of the Shuganjieyu group was significantly lower (OR: 0.22 (0.15, 0.32), p < 0.00001). In comparison of combination of Shuganjieyu capsule with regular antidepressant versus regular antidepressant alone, the 8, 6, 4, 2, and 1-week HAMD reduction and response rate of combination of Shuganjieyu with the regular antidepressant group were significantly larger (8-week MD: 3.2 (1.34, 5.06), p=0.0007; 6-week MD: 4.00 (2.72, 5.28), p < 0.00001; 4-week MD: 3.33 (1.94,4.73), p < 0.00001; 2-week MD: 2.69 (1.34, 4.03), p < 0.0001; 1-week MD: 2.27 (0.69, 3.86), p=0.005; and response rate OR: 4.69 (2.27, 9.68), p < 0.0001) and the adverse event rate was comparable for the two groups (OR: 1.26 (0.73, 2.17), p=0.41).Compared with regular antidepressants, single Shuganjieyu capsule has similar efficacy and better safety profile; when Shuganjieyu capsule is combined with regular antidepressants, the efficacy is improved significantly without increasing adverse events. Therefore, Shuganjieyu capsule was effective and safe for postpartum, making it worth further investigation and popularization.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
斯文的若颜完成签到,获得积分10
1秒前
yar应助怡然毛豆采纳,获得10
1秒前
zz完成签到,获得积分10
1秒前
3秒前
hjy驳回了SciGPT应助
3秒前
3秒前
3秒前
Hello应助M二十四采纳,获得10
4秒前
4秒前
量子星尘发布了新的文献求助10
4秒前
77完成签到,获得积分10
4秒前
5秒前
HEIEI完成签到,获得积分10
5秒前
6秒前
6秒前
zhaxiao发布了新的文献求助10
7秒前
chen发布了新的文献求助10
8秒前
陶醉安妮完成签到,获得积分10
8秒前
李爱国应助SXW采纳,获得10
9秒前
坚定萤完成签到,获得积分10
9秒前
华仔应助科研通管家采纳,获得10
9秒前
爆米花应助77采纳,获得50
9秒前
FashionBoy应助科研通管家采纳,获得10
9秒前
在水一方应助科研通管家采纳,获得10
9秒前
脑洞疼应助科研通管家采纳,获得10
9秒前
科研通AI2S应助科研通管家采纳,获得10
9秒前
李健应助科研通管家采纳,获得10
9秒前
领导范儿应助科研通管家采纳,获得10
10秒前
丘比特应助科研通管家采纳,获得10
10秒前
10秒前
10秒前
干饭大王应助科研通管家采纳,获得10
10秒前
10秒前
10秒前
10秒前
多金发布了新的文献求助10
11秒前
淡然冬灵发布了新的文献求助30
11秒前
夏火火完成签到,获得积分10
11秒前
斯文败类应助北还北采纳,获得10
11秒前
12秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974426
求助须知:如何正确求助?哪些是违规求助? 3518788
关于积分的说明 11195842
捐赠科研通 3254946
什么是DOI,文献DOI怎么找? 1797649
邀请新用户注册赠送积分活动 877037
科研通“疑难数据库(出版商)”最低求助积分说明 806130